Bicara Therapeutics Inc. filings document the regulatory record of a clinical-stage biopharmaceutical issuer developing bifunctional therapies for solid tumors. Forms 8-K record financial results, business highlights, ficerafusp alfa clinical updates, material definitive agreements and other events, including common stock and pre-funded warrant financing.
The company’s proxy materials cover annual meeting proposals, board-class elections, auditor ratification and governance matters for an emerging growth company. The filings also describe capital-structure actions and formal exhibits tied to press releases, underwriting agreements and shareholder voting matters.
Bicara Therapeutics Inc. officer David Raben reported a proposed sale of 24,777 common shares, with an approximate sale date of October 21, 2026. The notice lists Morgan Stanley Smith Barney LLC as broker and an aggregate market value of $449,026.14. It identifies the shares as acquired through a stock option exercise from the issuer on October 21, 2026, with cash shown as payment.
Bicara Therapeutics Inc. (BCAX) is the issuer in an ownership amendment where T. Rowe Price Investment Management, Inc. listed 2,804,772 common shares, or 4.2% of the class, as beneficially owned as of September 30, 2026. The firm reported sole voting power over 2,798,430 shares, no shared voting power, sole dispositive power over 2,804,772 shares, and no shared dispositive power; it expressly denied that the report should be construed as an admission that it is the beneficial owner.
Bicara Therapeutics Inc. (BCAX) officer Ryan Cohlhepp, President, COO and Interim CEO, exercised options to acquire 17,500 shares of common stock on September 8, 2026 at an exercise price of $3.7898 per share, leaving 34,252 options outstanding under that grant. On the same date he sold 14,058 shares at a weighted average price of $22.7666 per share and 3,442 shares at a weighted average price of $23.4349 per share in multiple transactions. These trades were made pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026, and the option underlying the exercise vests in sixteen equal quarterly installments following April 5, 2023, subject to continued service.
Bicara Therapeutics Inc. (BCAX) is the issuer for which a Form 144 notice has been filed regarding proposed sales of common stock for the account of Ivan Hyep. The filing indicates a planned sale of 12,500 common shares through UBS Financial Services Inc., with an aggregate market value of about $283,000.00 as of the filing. The shares are to be sold on or about September 8, 2026 and will be issued upon the exercise of stock options for cash. Over the prior three months, the same holder reported additional sales of 28,000 shares for $807,671.05 on July 8, 2026 and 12,500 shares for $349,591.25 on August 10, 2026.
Bicara Therapeutics Inc. (BCAX) insider Ryan Cohlhepp filed a Form 144 notice covering a proposed sale of 17,500 shares of common stock through UBS Financial Services Inc., with an estimated aggregate value of $396,200.00, expected on September 8, 2026 on NASDAQ.
The notice also lists prior sales of Bicara common stock by Ryan Cohlhepp over the past three months totaling 47,500 shares for aggregate proceeds of $1,357,661.48.
Bicara Therapeutics Inc. (BCAX) entered into a Sub-Sublease Agreement with Wayfair LLC to lease approximately 35,090 square feet of office space for its new corporate headquarters at 10 St. James Avenue, Boston, Massachusetts 02116. The sublease term will commence on the later of October 1, 2026 or the date a required multi-party consent is fully executed, defined as the Commencement Date. The base rent is $105,279 per month, beginning nine months after the Commencement Date, and Bicara paid a $210,540 security deposit at signing. The sublease will end on the earlier of September 30, 2028 or an earlier termination under its terms and includes customary events of default, representations, warranties and covenants.
Bicara Therapeutics Inc. reported that its Chief Financial Officer, Jennifer Larson, received a grant of 285,000 stock options on August 12, 2026. The options have an exercise price of $24.63 per share and are exercisable for an equal number of shares of common stock until August 12, 2036. According to the vesting terms, 25% of the options vest and become exercisable on August 12, 2027, with the remaining 75% vesting in twelve equal quarterly installments thereafter, subject to her continued service. Following this award, she holds 285,000 derivative securities of this type directly.
Bicara Therapeutics Inc. reported the initial insider ownership status of its Chief Financial Officer, Jennifer Larson, through a Form 3. The filing lists her as an officer but shows no reportable equity holdings or transactions at this time. It also references an attached Exhibit 24 granting a Power of Attorney.
Janus Henderson Group Ltd. reports beneficial ownership of Bicara Therapeutics Inc. common stock on a passive basis. Through its investment adviser subsidiaries managing various Managed Portfolios, it may be deemed to beneficially own 3,171,015 shares of common stock, representing 4.8% of the class. All voting and dispositive authority over these shares is shared among the relevant asset managers; none is held on a sole basis. Janus Henderson and its asset managers disclaim rights to receive dividends or sale proceeds, which belong to the Managed Portfolios. No individual Managed Portfolio holds more than five percent of Bicara’s common stock.
Bicara Therapeutics Inc. Chief Financial Officer Hyep Ivan exercised stock options for 12,500 shares of common stock at an exercise price of $3.7898 per share and on the same day sold 12,500 shares at a weighted average price of $27.9673 per share. The option exercise reduced the reported option position to 26,336 stock options following the transaction, with the options expiring on April 5, 2033 and vesting in sixteen equal quarterly installments following April 5, 2023. The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026.